Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2025 | June 12, 2026 |
| Medtronic plcMDT · Entity 2888 | Director | April 27, 2026 | April 29, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Director | May 06, 2026 | May 08, 2026 |
| abrdn Healthcare InvestorsHQH · Entity 8816 | Director | December 13, 2018 | December 19, 2018 |
| abrdn Healthcare Opportunities FundTHQ · Entity 5102 | Director | December 13, 2018 | December 19, 2018 |
| abrdn Life Sciences InvestorsHQL · Entity 8835 | Director | December 13, 2018 | December 19, 2018 |
| abrdn World Healthcare FundTHW · Entity 5390 | Director | December 13, 2018 | December 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date June 10, 2025 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Medtronic plc
Report date April 27, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,791 |
Reported balance
After 2026-04-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-27 · Grant · Acquired 2,111 · Balance 19,791 F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,584 |
Reported balance
After 2026-04-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-04-28 · Tax withholding · Disposed 207 · Balance 19,584 F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.
F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.
F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.
Moderna, Inc.
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,371 |
Reported balance
After 2026-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 8,371 · Balance 8,371 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
abrdn Healthcare Investors
Report date December 13, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 2,417 |
Reported balance
Holding disclosure · report date 2018-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,417 |
abrdn Healthcare Opportunities Fund
Report date December 13, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 2,816 |
Reported balance
Holding disclosure · report date 2018-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,816 |
abrdn Life Sciences Investors
Report date December 13, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 2,787 |
Reported balance
Holding disclosure · report date 2018-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,787 |
abrdn World Healthcare Fund
Report date December 13, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 3,799 |
Reported balance
Holding disclosure · report date 2018-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,799 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Accolade, Inc.
Report date April 08, 2025 · Filed April 08, 2025
Section 16 reporting ended · disclosed 2025-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-08 transaction · row 1
1 source rowRow 1 · 2025-04-08 · Disposition to issuer · Disposed 41,982 · Balance 0 F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2025, by and among Issuer, Transcarent, Inc. ("Parent") and Acorn Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on April 8, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $7.03 in cash, without interest (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-08 · Disposition to issuer · Disposed 35,021 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F3: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-08 · Disposition to issuer · Disposed 12,489 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F5: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2025, by and among Issuer, Transcarent, Inc. ("Parent") and Acorn Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on April 8, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $7.03 in cash, without interest (the "Merger Consideration").
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F3: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings.
F5: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2023 Filed May 3, 2023 20:31 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 169 | $90.23 | $15,248.87 |
DisclosureSEC source: 0001613103-23-000020 · wf-form4_168314585980107.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,635 F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:31 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,930 | $90.68 | $175,012.40 |
DisclosureSEC source: 0001613103-23-000020 · wf-form4_168314585980107.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,804 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 56 units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013930 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 670 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2023. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:43 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-013930 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 13:05 UTC | Accolade, Inc. ACCD · Entity 80959 | GrantRestricted Stock Units · Derivative | 7,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008187 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006 Underlying: Common Stock · 7,006 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F1 · price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F2 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F2 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 13:17 UTC | Accolade, Inc. ACCD · Entity 80959 | GrantRestricted Stock Units · Derivative | 14,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019813 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,060 Underlying: Common Stock · 14,060 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F1 · price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F2 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. F2 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 14:24 UTC | Accolade, Inc. ACCD · Entity 80959 | Exercise / conversionRestricted Stock Units · Derivative | 2,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019721 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. F3 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 14:24 UTC | Accolade, Inc. ACCD · Entity 80959 | Exercise / conversionCommon Stock | 2,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019721 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:14 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001209191-22-035858 · doc4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:23 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 262 | $103.11 | $27,014.82 |
DisclosureSEC source: 0001127602-22-013317 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 F1 · balance_after: This balance increased by 30 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:23 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013317 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,080 Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012852 · form4.xml · derivative · entry 4 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670 Underlying: Common Stock · 670 shares Expires not disclosed F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,061 | $0.00 Strike: $142.52 | $0.00 |
DisclosureSEC source: 0001127602-22-012852 · form4.xml · derivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 4,061 shares Expires not disclosed F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012852 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012852 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 13:42 UTC | Accolade, Inc. ACCD · Entity 80959 | GrantRestricted Stock Units · Derivative | 2,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-022483 · form4.xml · derivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,659 Underlying: Common Stock · 2,659 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. F3 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 13:42 UTC | Accolade, Inc. ACCD · Entity 80959 | Exercise / conversionRestricted Stock Units · Derivative | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-022483 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") vested and converted into one share of the Issuer's Common Stock on July 22, 2021. F1 · price: Each restricted stock unit ("RSU") vested and converted into one share of the Issuer's Common Stock on July 22, 2021. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") vested and converted into one share of the Issuer's Common Stock on July 22, 2021. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") vested and converted into one share of the Issuer's Common Stock on July 22, 2021. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 13:42 UTC | Accolade, Inc. ACCD · Entity 80959 | Exercise / conversionCommon Stock | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-022483 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") vested and converted into one share of the Issuer's Common Stock on July 22, 2021. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 17:24 UTC | Accolade, Inc. ACCD · Entity 80959 | GrantRestricted Stock Units · Derivative | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-019031 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346 Underlying: Common Stock · 346 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Common Stock upon vesting of the RSU. F2 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. F2 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:54 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015326 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,353 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014771 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock · 703 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,081 | $0.00 Strike: $178.68 | $0.00 |
DisclosureSEC source: 0001127602-21-014771 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 4,081 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:34 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 426 | $129.97 | $55,367.22 |
DisclosureSEC source: 0001127602-21-014586 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,019 F1 · balance_after: This balance increased by 37 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 21:52 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 1,139 | $0.00 Strike: $129.75 | $0.00 |
DisclosureSEC source: 0001127602-21-010246 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139 Underlying: Common Stock · 1,139 shares Expires 2031-03-10 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,948 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · derivative · entry 7 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,376 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · derivative · entry 6 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,376 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,307 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · derivative · entry 5 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,307 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F2 · derivative.exercise_date: This option will become fully vested and exercisable on February 28, 2019. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 73,975 | $87.84 | $6,497,964.00 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · nonDerivative · entry 4 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,948 | $19.15 | $209,654.20 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · nonDerivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 8,376 | $19.15 | $160,400.40 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 40,307 | $14.22 | $573,165.54 |
DisclosureSEC source: 0001127602-20-021761 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 30,000 | $66.00 | $1,980,000.00 |
DisclosureSEC source: 0001127602-20-016607 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,344 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 12, 2020 Filed Jun 5, 2020 01:45 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 30,000 | $66.00 | $1,980,000.00 |
DisclosureSEC source: 0001127602-20-018935 · form4a.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,344 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2020. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 21:35 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 18,270 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001127602-20-014885 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,270 Underlying: Common Stock · 18,270 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 22:38 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 393 | $99.14 | $38,962.02 |
DisclosureSEC source: 0001127602-20-014922 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,408 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 22:27 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014691 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,801 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 41 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:17 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023019 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:26 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016733 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 22:15 UTC Amendment | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021495 · form4a.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:26 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016733 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,452 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 50 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed Jun 12, 2019 22:15 UTC Amendment | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021495 · form4a.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,452 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 50 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries G Preferred Stock · Derivative | 13,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030873 · doc4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,679 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionCommon Stock | 13,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030873 · doc4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| May 01, 2018 Filed May 2, 2018 19:05 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 616 | $81.01 | $49,902.16 |
DisclosureSEC source: 0001127602-18-015924 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Read SEC document |
| April 30, 2018 Filed May 2, 2018 19:05 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015924 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,016 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 48 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 02, 2017 Filed May 4, 2017 18:18 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016839 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,784 Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:03 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016602 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,434 F1 · security: This balance increased by 48 shares due to exempt transactions such as dividend reinvestment. F2 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.